Research ArticleDrug Discovery and Translational Medicine
Open Access
Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity
Jaromir Vlach, Andrew T. Bender, Melinda Przetak, Albertina Pereira, Aditee Deshpande, Theresa L. Johnson, Sonja Reissig, Evgeni Tzvetkov, Djordje Musil, Noune Tahmassian Morse, Philipp Haselmayer, Simone C. Zimmerli, Shinji L. Okitsu, Robert L. Walsky and Brian Sherer
Journal of Pharmacology and Experimental Therapeutics March 2021, 376 (3) 397-409; DOI: https://doi.org/10.1124/jpet.120.000275
Jaromir Vlach
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Andrew T. Bender
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Melinda Przetak
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Albertina Pereira
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Aditee Deshpande
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Theresa L. Johnson
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Sonja Reissig
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Evgeni Tzvetkov
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Djordje Musil
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Noune Tahmassian Morse
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Philipp Haselmayer
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Simone C. Zimmerli
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Shinji L. Okitsu
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Robert L. Walsky
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)
Brian Sherer
EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor
Jaromir Vlach, Andrew T. Bender, Melinda Przetak, Albertina Pereira, Aditee Deshpande, Theresa L. Johnson, Sonja Reissig, Evgeni Tzvetkov, Djordje Musil, Noune Tahmassian Morse, Philipp Haselmayer, Simone C. Zimmerli, Shinji L. Okitsu, Robert L. Walsky and Brian Sherer
Journal of Pharmacology and Experimental Therapeutics March 1, 2021, 376 (3) 397-409; DOI: https://doi.org/10.1124/jpet.120.000275
Research ArticleDrug Discovery and Translational Medicine
M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor
Jaromir Vlach, Andrew T. Bender, Melinda Przetak, Albertina Pereira, Aditee Deshpande, Theresa L. Johnson, Sonja Reissig, Evgeni Tzvetkov, Djordje Musil, Noune Tahmassian Morse, Philipp Haselmayer, Simone C. Zimmerli, Shinji L. Okitsu, Robert L. Walsky and Brian Sherer
Journal of Pharmacology and Experimental Therapeutics March 1, 2021, 376 (3) 397-409; DOI: https://doi.org/10.1124/jpet.120.000275
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement